A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice

被引：8

作者：

Andjelic, Bosko ^{[1
]}

Antic, Darko ^{[1
,2
]}

Jakovic, Ljubomir ^{[1
]}

Todorovic, Milena ^{[1
,2
]}

Bogdanovic, Andrija ^{[1
,2
]}

Djurasinovic, Vladislava ^{[1
]}

Bila, Jelena ^{[1
,2
]}

Mihaljevic, Biljana ^{[1
,2
]}

机构：

[1] Clin Ctr Serbia, Clin Hematol, Belgrade 11000, Serbia

[2] Univ Belgrade, Fac Med, Belgrade, Serbia

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2014年 / 93卷 / 05期

关键词：

advanced Hodgkin lymphoma; ABVD; daily practice; PROGNOSTIC SCORE; STANFORD-V; STAGE; CHEMOTHERAPY; TRIAL; INTENSIFICATION; BEACOPP; RADIOTHERAPY; MACROPHAGES; THERAPY;

D O I：

10.1111/ejh.12364

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Based on the results of clinical trials, there is no global consensus on the optimal first-line therapy for patients with advanced Hodgkin lymphoma (HL) with both ABVD and BEACOPP currently being used. However, the results of clinical trials are usually better than those in daily practice. We thus describe here our experience on 314 advanced classical HL patients treated with ABVD at the Clinical Center of Serbia and associated centers between 1997 and 2008. The median follow-up for all patients was 91months; the estimated 5-yr event-free survival was 62% and the 5-yr overall survival (OS) 76%. Multivariate Cox regression analysis revealed that patients with IPS3 and extranodal disease involving more than one site have a poorer outcome. The data presented here show on overall improvement in outcome as compared to more previous data and illustrate the problems of treating advanced stage HL outside the setting of a clinical trial.

引用

页码：392 / 399

页数：8

共 32 条

[1] Induction Therapy for Advanced-stage Hodgkin Lymphoma Late Intensification (ABVD Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplant Only for Those Who Relapse) [J].

Ansell, Stephen M. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) :75-+

[2] Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma [J].

Avigdor, A. ;

Bulvik, S. ;

Levi, I. ;

Dann, E. J. ;

Shemtov, N. ;

Perez-Avraham, G. ;

Shimoni, A. ;

Nagler, A. ;

Ben-Bassat, I. ;

Polliack, A. .

ANNALS OF ONCOLOGY, 2010, 21 (01) :126-132

[3] Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma [J].

Borchmann, Peter .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) :65-+

[4] Managing relapsed and refractory Hodgkin lymphoma [J].

Brice, Pauline .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (01) :3-13

[5]

Brillant C, 2007, ASH ANN M, V110

[6] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].

CANELLOS, GP ;

ANDERSON, JR ;

PROPERT, KJ ;

NISSEN, N ;

COOPER, MR ;

HENDERSON, ES ;

GREEN, MR ;

GOTTLIEB, A ;

PETERSON, BA .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484

[7]

Carde P, 2012, J CLIN ONCOL S15, V30

[8] Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma [J].

Chen, Robert ;

Palmer, Joycelynne M. ;

Thomas, Sandra H. ;

Tsai, Ni-Chun ;

Farol, Len ;

Nademanee, Auayporn ;

Forman, Stephen J. ;

Gopal, Ajay K. .

BLOOD, 2012, 119 (26) :6379-6381

[9] HEMATOLOGY Are macrophages the bad guys in Hodgkin lymphoma? [J].

Diehl, Volker .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (06) :301-302

[10] Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Eichenauer, D. A. ;

Engert, A. ;

Dreyling, M. .

ANNALS OF ONCOLOGY, 2011, 22 :vi55-vi58

← 1 2 3 4 →